BIOMAT Database Logo BIOMAT Database Logo

[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor]. 1993

N B Liu
China-Japan Friendship Hospital, Beijing.

Multidrug-resistance of the tumor cells is the main cause for failure of chemotherapy. Such resistance is correlated to P-glycoprotein 170, which can pump the chemotherapeutic agent out of the tumor cells. This action could be reversed by verapamil through competition for closely related binding sites on P-glycoprotein. Twenty-four postoperative cases of superficial bladder tumors were treated by intravesical instillation of combined adriamycin and verapamil, and they were followed up for 17-35 months (average 24.5 months). Two cases (8.7%) had recurrence. NO marked toxicity and side-effects were observed. Verapamil working as a drug-resistance reversing agent might be used in some other tumors not sensitive to chemotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females

Related Publications

N B Liu
Intravesical instillation of adriamycin combined with low-dose irradiation for superficial bladder cancer.
June 1980, Urology,
N B Liu
[Intravesical instillation of adriamycin and its concentration in bladder tumor].
June 1983, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
N B Liu
[The treatment of superficial bladder carcinoma with intravesical HPC-adriamycin and verapamil].
March 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
N B Liu
[Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer].
April 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
N B Liu
[A comparative clinical trial of UFT treatment and intravesical adriamycin instillation to prevent recurrence of superficial bladder cancer].
April 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
N B Liu
Intravesical instillation of adriamycin for bladder tumors.
January 1992, Cancer chemotherapy and pharmacology,
N B Liu
[Prevention of recurrence in urinary bladder tumors by intravesical instillation treatment with adriamycin].
January 1985, Der Urologe. Ausg. A,
N B Liu
[Prophylaxis of recurrence of superficial bladder tumor by diluted postoperative continuous intravesical instillation of anti-tumor solutions].
March 1985, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
N B Liu
P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder.
January 2003, Anticancer research,
N B Liu
Re: Recurrence of superficial bladder carcinoma after intravesical instillation of Mitomycin-C.
December 1989, British journal of urology,
Copied contents to your clipboard!